this study, we investigated the mechanism of PGE 2 production and the induction of suppressor macrophages in the glioma-bearing state.
Materials and Methods

Study Population
Seven-to 10-week-old female C57BL/6N and C3H/HeN mice were purchased from a commercial provider (Seac, Ohita, Japan). The mPGES-1-deficient female C57BL/6 mice were provided by Dr. S. Akira (Osaka University, Osaka, Japan). 41 These mice were maintained in the Animal Research Center at the University of Occupational and Environmental Health, Kitakyusyu, Japan, under specific pathogen-free conditions. All animal experiments were performed according to the guidelines for the care and use of animals approved by the University of Occupational and Environmental Health.
Reagents and Cell Lines
Indomethacin, anti-COX-2 antibody, anti-mPGES-1 antibody, and anti-cPGES antibody were purchased from Cayman Chemicals (Ann Arbor, MI). The LPS (Escherichia coli serotype 055:B5) and papain were purchased from Sigma-Aldrich (St. Louis, MO).
We used U251, human malignant astrocytoma; T98G, human glioblastoma multiforme; VM glioma; spontaneously induced astrocytoma originating in VM mice (H-2 b ); RSV-M: malignant glioma originating in C3H/HeN mice (H-2 k ) and induced by Schmitt-Ruppin RSV; and X5563, plasmacytoma originating in C3H/HeN mice (H-2 k ). These cell lines were continuously maintained in RPMI-1640 medium (Nissui Pharmaceutical, Tokyo, Japan) containing 10% FCS (BioWhittaker, Walkersville, MD), 2 mM L-glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin (all from Life Technologies, Rockville, MD). The VM glioma was provided by Dr. T. Yamasaki (Shimane University, Shimane, Japan), 28 and the RSV-M was provided by Dr. K. Shimizu (Kochi University, Kochi, Japan). 42 
Preparation of Human PBMCs
Human PBMCs were isolated from healthy donors by using density gradient centrifugation with lymphocyte separation medium (Nakarai Tesque, Kyoto, Japan). Cells were collected at the interface, washed twice with Hanks balanced salt solution (Nissui Pharmaceutical), and resuspended in RPMI-10% FCS medium. Human PBMCs (2 ϫ 10 6 /500 l/well), human glioma cells (5 ϫ 10 4 /500 l/ well), and mixtures of these cells were cultured in a 24-well culture plate for 6 hours, and then treated with or without LPS (0.1 g/ml) for an additional 18 hours at 37˚C in 5% CO 2 and 95% air. The cellfree culture supernatants were collected and used for the PGE 2 assay, as described later.
Preparation of Macrophages
Peritoneal exudate cells were harvested from C57BL/6N or mPGES-1-deficient C57BL/6 mice 3 days after the intraperitoneal injection of 2 ml 4% thioglycolate broth (Eiken, Tokyo, Japan). Cells were resuspended in RPMI-10% FCS medium, 2 mM glutamine, 50 U/ml penicillin, and 50 g/ml streptomycin and were seeded into 24-well (Falcon 3047; BD Biosciences, Franklin Lakes, NJ) or six-well plates (Falcon 3046; BD Biosciences). The cells were then cultured at 37˚C in 5% CO 2 for 1.5 hours, nonadherent cells were washed out with warm Hanks balanced salt solution, and adherent cells were used as macrophages. This adherent cell population contained more than 95% Mac-1 ϩ cells, as detected by flow cytometry.
Preparation of Conditioned Glioma Medium
The VM glioma and RSV-M (2 ϫ 10 5 /ml) were cultured in RPMI-1640 medium with or without 10% FCS at 37˚C in 5% CO 2 and 95% air for 48 hours, and the supernatant was used as the conditioned glioma medium after filtration through a 0.2-m cellulose acetate membrane (Millipore, Tokyo, Japan).
In Vitro Culture of Cells
Peritoneal macrophages (5 ϫ 10 5 /500 l/well), murine glioma cells (5 ϫ 10 4 /500 l/well), and mixtures of both types of cells were cultured in 24-well culture plates with or without indomethacin (1 M) for 6 hours, and then treated with or without LPS (1 g/ml) for an additional 18 hours at 37˚C in 5% CO 2 and 95% air. The same method was applied using a cell culture insert (Falcon 3104; BD Biosciences) or the conditioned glioma medium instead of glioma cells. The cell-free culture supernatants were collected and subjected to the assay of PGE 2 and cytokines, which are subsequently described; cell lysates were subjected to Western blotting, also described later. For mRNA analysis, peritoneal macrophages (2 ϫ 10 6 /2000 l/well) were cultured in a six-well culture plate with or without the conditioned glioma medium for 6 hours, and then treated with or without LPS (1 g/ml) for an additional 18 hours at 37˚C in 5% CO 2 and 95% air. Total cellular RNA was used for mRNA analysis, as described later.
Heat and Papain Treatment of Conditioned Glioma Medium
The FCS-free conditioned glioma medium was heated in a commercially available unit (Dry Thermo Unit; Taitec, Tokyo, Japan) for 30 minutes at 56˚C or 100˚C or treated with papain (0.2 mg/ml) for 24 hours at 37˚C. The ability of these treated conditioned media to enhance the macrophagic production of PGE 2 from C57BL/6N mice when added together with LPS (1 g/ml) for 18 hours at 37˚C in 5% CO 2 and 95% air was tested.
Prostaglandin E 2 and Cytokine Assay
Prostaglandin E 2 was measured using a commercially available EIA kit (STAT-PGE 2 ; Cayman Chemicals), according to the manufacturer's protocol. The TNF was measured using a cytotoxicity assay with L929 cells, based on the method of Flick and Gifford. 7 The IL-12p70 was treated using ELISA with anti-mouse IL-12p35 mAb as the capture antibody, biotin-labeled anti-mouse IL-12p40 mAb as the detection antibody, and streptavidin-conjugated alkaline phosphatase (PharMingen, San Diego, CA) and p-nitrophenylphoshate (Zymed Laboratory, San Francisco, CA) as the substrates.
Cytotoxic T Cell Assay
Peritoneal macrophages harvested from C3H/HeN mice 3 days after the intraperitoneal injection of 2 ml 4% thioglycolate broth were treated with mitomycin C (50 g/ml; Kyowa Hakko Kogyo Co., Tokyo, Japan) at 37˚C for 60 minutes, and then treated with 2,4,6-trinitrobenzene sulfonate (5 mM) in phosphate-buffered saline (pH 7.4) for TNP coupling at 37˚C for 10 minutes. Responder spleen cells (6 ϫ 10 6 /well) from C3H/HeN mice were cultured with TNPmodified or unmodified stimulator cells (10 5 /well) in a 24-well culture plate in 2 ml Peck-Click culture medium containing 10% FCS (as described by Corradin, et al. 4 ) for 4 days at 37˚C in 5% CO 2 and 95% air. Conditioned glioma medium (10%) or indomethacin (1 M) was added during the induction phase of cytotoxic T cells. The X5563 tumor cells were used as target cells for the cytotoxic T cells. 44 Target cells were labeled with 100 Ci Na 2
51
CrO 4 (Perkin Elmer, Boston, MA) at 37˚C for 1.5 hours, and then treated with 2,4, 6-trinitrobenzene sulfonate (2 mM) at 37˚C for 10 minutes. These treated target cells (2 ϫ 10 4 /well) were mixed with effector T cells (5 ϫ 10 5 /well), which had been cultured for 4 days, in 0.2 ml RPMI-10% FCS medium in a 96-well U-bottomed plate (Falcon 3077; BD Biosciences). All determinations were performed in triplicate. After effector-target cell interaction for 5 hours at 37˚C in 5% CO 2 and 95% air, the plates were centrifuged at 1500 rpm for 10 minutes, the culture supernatant in each well was harvested, and the radioactivity in the culture supernatant was counted using a gamma counter (ARC-7001; Aloka, Tokyo, Japan). The percentage of specific lysis was calculated using the following formula: [(experimental release Ϫ spontaneous release)/(maximal release Ϫ spontaneous release)] ϫ 100. The maximal release was obtained by adding 1% Triton X-100 (Sigma-Aldrich) to the labeled target cells. The spontaneous release was obtained by incubating the labeled target cells with medium in the absence of effector T cells. Prostaglandin E 2 production in the culture supernatant was measured using EIA on Day 2 of the culture of responder spleen cells with stimulator cells.
Messenger RNA Analysis
Messenger RNA expression was detected by reverse transcription-PCR. Total cellular RNA was extracted using an AquaPure RNA isolation kit (Bio-Rad Laboratories, Irvine, CA), according to the manufacturer's protocol. First-strand complementary DNA was synthesized from 5 g total RNA by using Superscript II RNase Hreverse transcriptase (Life Technologies), following the instructions from the manufacturer and using 0.25 g random primer (Life Technologies). One tenth of the synthesized complementary DNA was amplified by PCR using 50 pmol each of sense and antisense primers with 1 U Taq polymerase (Boehringer Mannheim, Mannheim, Germany) in a total volume of 50 l. Each PCR cycle consisted of incubation for 1 minute at 94˚C for denaturation, 1 minute at 55˚C for annealing, and 2 minutes at 72˚C for extension; at the first cycle, denaturation was performed for 2 minutes at 94˚C. The sequence of the sense and antisense primers, product size, and number of PCR cycles were as follows: GAPDH, 5Ј-ACCACAGTCCATGCCATCAC-3Ј and 5Ј-TCCACCACCCTGTTGCTGTA-3Ј, 452 bp, 20 cycles; mPGES-1, 5Ј-AGCACACTGCTGGTCATCAAGATGTAC-3Ј and 5Ј-CCTGTGAGGACAACGAGGAAATGTATC-3Ј, 269 bp, 24 cycles; COX-2, 5Ј-ACTCACTCAGTTTGTTGAGTCATTC-3Ј and 5Ј-TTTGATTAGTACTGTAGGGTTAATG-3Ј, 583 bp, 26 cycles; COX-1, 5Ј-TGCATGTGGCTGTGGATGTCATCAA-3Ј and 5Ј-CACTAAGACAGACCCGTCATCTCCA-3Ј, 449 bp, 34 cycles; cPLA 2 , 5Ј-TGTTCAACAGAGTTTTGG-3Ј and 5Ј-AACAGAG-CAACGAGATGG-3Ј, 983 bp, 34 cycles; and sPLA 2 Type V, 5Ј-CAGGGGGCTTGCTAGAACTCAA-3Ј and 5Ј-AAGAGGGTT-GTAAGTCCAGAGG-3Ј, 329 bp, 30 cycles. A 12-l aliquot of PCR products was electrophoresed on a 1.5% agarose gel. After ethidium bromide staining (Sigma-Aldrich), PCR products were visualized using ultraviolet illumination.
Western Blot Analysis
Cells were lysed with 100 l sodium dodecyl sulfate (Nacarai Tesque). The lysates were boiled for 10 minutes, resolved by 5 to 20% SDS-PAGE (Nacarai Tesque) with e-PAGEL (ATTO, Tokyo, Japan), transferred to a polyvinylidene difluoride membrane (BioRad Laboratories), and blotted with anti-COX-2 antibody (1000 ϫ dilution), anti-mPGES-1 antibody (1000 ϫ dilution), or anti-cPGES (1000 ϫ dilution), and horseradish peroxidase-conjugated secondary antibody (1000 ϫ dilution). The reactive bands were visualized using Lumi-LightPLUS Western blotting substrate (Roche Diagnostics, Indianapolis, IN) as a substrate and Fluorochem (Alpha Innotech, San Leandro, CA) as a detector. 20 
Statistical Analysis
All experiments were repeated at least three times, and one representative result from each experiment is shown in the figures. All determinations were made in triplicate and each result was expressed as the mean Ϯ standard error of the mean. Statistical analyses were performed using the Student t-test, and a confidence level of less than 0.05 was considered significant.
Results
Enhancement of PGE 2 Production by Murine Macrophages Cocultured With Glioma
At first, we investigated PGE 2 production by murine macrophages cocultured with glioma cells. Peritoneal macrophages were cocultured with glioma cells treated with or without LPS. As shown in Fig. 1 , glioma cells produced only a small amount of PGE 2 by themselves. The PGE 2 production by macrophages was markedly enhanced by coculturing with glioma cells. Stimulation with LPS further enhanced PGE 2 production. This enhancement of PGE 2 production by macrophages depended on the number of glioma cells.
Soluble Mediators From Glioma Enhanced Macrophagic PGE 2 Production
To study the mechanism of the enhancement of PGE 2 production by macrophages cocultured with glioma cells, we performed experiments using a cell culture insert. Macrophages were cocultured with glioma cells treated with or without LPS in the presence or absence of a cell culture insert. The PGE 2 production by macrophages was significantly enhanced by coculturing with glioma cells regardless of whether a cell culture insert was present ( Fig. 2A and B) , suggesting that direct contact between macrophages and glioma cells is not required to enhance PGE 2 production. To confirm this phenomenon, we used conditioned glioma medium. As shown in Fig. 2C and D, PGE 2 production by macrophages was dose-dependently enhanced by the conditioned glioma medium. These results suggested that the enhancement of PGE 2 production by macrophages is mediated by soluble factors in the conditioned glioma medium. To study the characteristics of these glioma-derived soluble factors, we subjected the conditioned medium to several types of treatment. Dialysis of the conditioned medium did not reduce its activity (data not shown), suggesting that a large molecule participates in its activity. Treatment of the conditioned medium at 56˚C for 30 minutes slightly, and treatment at 100˚C for 30 minutes significantly, reduced its activity (Fig. 3A and B) . Moreover, treatment of the conditioned medium with papain also significantly reduced its activity (Fig. 3C) . These results indicated that the gliomaderived soluble factors are sensitive to heat and papain treatment.
Suppression and Restoration of TNF and IL-12 Production by Macrophages
Next, we studied cytokine production by macrophages treated with conditioned glioma medium. As shown in Fig.  4 , TNF and IL-12 production by macrophages was significantly suppressed by coculturing with the conditioned glioma medium. Indomethacin, a COX inhibitor, abrogated the suppression of TNF and IL-12 production. As expected, PGE 2 production was suppressed by indomethacin. These results indicated that the production of TNF and IL-12, im- ; B) for 6 hours, and then stimulated with (black bars) or without (white bars) LPS (1 g/ml) for 18 hours. Production of PGE 2 was detected using EIA. Production was significantly enhanced compared with the control group (*p Ͻ 0.01 and **p Ͻ 0.05).
portant cytokines for anti-tumor effects, is suppressed by enhanced macrophagic PGE 2 production.
Suppression of Cytotoxic T Cell Induction by the Enhanced PGE 2 Production
The TNP-specific cytotoxic T cells were induced by the culture of responder spleen cells with TNP-modified stimulator peritoneal macrophages in the presence or absence of conditioned glioma medium. Prostaglandin E 2 production was again enhanced by the presence of conditioned glioma medium (Fig. 5A and C) . The TNP-specific cytotoxic T cells were suppressed by the presence of the conditioned medium; this suppression was overcome by indomethacin ( Fig. 5B and D) . These results indicated that the induction of cytotoxic T cells is suppressed by the enhanced production of PGE 2 by macrophages treated with the conditioned glioma medium.
Expression of COX-2 and mPGES-1 in Macrophages Treated With Conditioned Glioma Medium
It is known that COX-2 and mPGES-1 are inducible enzymes and that mPGES-1 is preferentially coupled with inducible COX-2 to promote the final step in PGE 2 biosynthesis. We examined whether the expressions of COX-2, mPGES-1, and other PGE 2 biosynthetic enzymes were induced by the conditioned glioma medium. The expression of both COX-2 and mPGES-1 was augmented by the con-
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Prostaglandin E 2 production by glioma-treated macrophages 577 FIG. 3. Bar graphs depicting the characteristics of glioma-derived soluble factors. Conditioned glioma medium was treated at 56˚C or 100˚C for 30 minutes, and PGE 2 production by macrophages cultured with the heat-treated conditioned medium plus LPS (1 g/ml) was compared with production induced by the untreated conditioned medium plus LPS (A and B). Conditioned glioma medium was treated (black bars) or not treated (white bars) with papain (0.2 mg/ml) for 24 hours. The PGE 2 production by macrophages cultured with the papain-treated medium plus LPS (1 g/ml) was compared with the production induced by the untreated conditioned medium plus LPS (C). Production was significantly reduced compared with the untreated group (*p Ͻ 0.01). ditioned glioma medium, with the expression of mPGES-1 being more markedly enhanced. Note, however, that the expression of cPLA 2 , sPLA 2 Type V, COX-1, and cPGES/p23 was not changed (Fig. 6A and B) .
Prostaglandin E 2 and IL-12 Production in Macrophages From mPGES-1-Deficient Mice
To confirm the role of mPGES-1 in the suppression of the antiglioma effect, we studied PGE 2 and IL-12 production by using macrophages from mPGES-1-deficient mice. Prostaglandin E 2 was not induced in macrophages from mPGES-1-deficient mice, and IL-12 production was not clearly suppressed by the coculture of these macrophages with the conditioned glioma medium (Fig. 7A and B) . These results indicated that mPGES-1 is one of the important targets for the induction of antiglioma activity.
Prostaglandin E 2 Production by Human PBMCs
Finally, we studied PGE 2 production by human PBMCs cocultured with glioma. As shown in Fig. 8A and B, U251 and T98G human glioma cells themselves produced only a small amount of PGE 2 . However, PBMCs produced a large amount of PGE 2 when cocultured with glioma cells treated with or without LPS. Conditioned glioma medium also had a similar effect (Fig. 8C) . These results suggested that the enhanced production of PGE 2 by macrophages cocultured with glioma is a general phenomenon.
Discussion
In this study, we considered PGE 2 to be one of the key factors in the regulation of immune responses against glioma and studied the mechanism of PGE 2 production in glioma-bearing states. We found that glioma cells did not produce as much PGE 2 as that shown in many previous reports. 10, 22 Interestingly, however, when PBMCs or macrophages and glioma cells were cocultured in vitro, PGE 2 production was markedly enhanced (Fig. 1) . A cell culture insert did not disrupt PGE 2 production, and the conditioned glioma medium enhanced PGE 2 production, suggesting that the enhanced PGE 2 production by macrophages is mediated by glioma-derived soluble factors (Fig. 2) . The conditioned glioma medium suppressed the macrophagic production of ) were cocultured with conditioned glioma medium in the presence or absence of indomethacin (1 M) for 6 hours and then treated with (black bars) or without (white bars) LPS (1 g/ml) for 18 hours. Production of TNF was detected using an L929 bioassay (A and B). Production of IL-12 was detected using ELISA (C and D). Production of PGE 2 was detected using EIA (E and F). Production was significantly suppressed compared with the control group (*p Ͻ 0.01). Production was significantly enhanced compared with the indomethacin group ( †p Ͻ 0.01 and † †p Ͻ 0.05). Indo. = indomethacin. TNF and IL-12, important cytokines for tumor immunity, and this suppression was abrogated by indomethacin, a COX inhibitor (Fig. 4) . Furthermore, the conditioned glioma medium suppressed the induction of TNP-specific cytotoxic T cells, a model system for tumor antigen-specific T cells; this suppression was also overcome by indomethacin (Fig. 5) .
The glioma-derived soluble factors found in this study are dialysis membrane-impermeable and sensitive to heat and papain treatment, suggesting that they are proteins (Fig.  3) . We also found that several types of tumor cells, such as EL-4 thymoma, MH-134 hepatoma, and MBT-2 bladder cancer, also produce similar soluble factors (data not shown). Several reports have indicated that tumor cells produce many kinds of soluble factors such as TGF␤ and cytokines. 14, 21, 23 Among these cytokines, IL-1 and TNF are reported to stimulate macrophages to produce PGE 2 . 34 Note, however, that the glioma cells studied in the present report did not produce these cytokines (Table 1) ) from C57BL/6N or mPGES-1-deficient mice were cocultured with conditioned glioma medium for 6 hours, and then treated with (black bars) or without (white bars) LPS (1 g/ml) for 18 hours. Production of PGE 2 was detected using EIA (A). Production of IL-12 was detected using ELISA (B). Production was significantly suppressed compared with that in the control group (*p Ͻ 0.01). ) were cocultured with the conditioned glioma medium (50%) for 6 hours and treated with or without LPS (1 g/ml) for 18 hours. After this treatment (A), total RNA was extracted from cells, and each mRNA was detected by reverse transcription-PCR. The graphs show the relative amount of each expression normalized by GAPDH (G3PDH). After stimulation (B), the cell lysates were prepared, resolved by 5-20% SDS-PAGE, transferred to a membrane, and immunoblotted with anti-mPGES-1, anti-COX-2, or anti-cPGES/p23 antibody. The graphs show the units of density of the expression.
tibodies to these cytokines did not inhibit the PGE 2 -inducing activity of the conditioned glioma medium (data not shown). Kambayashi, et al., 14 and Maeda, et al., 23 reported that tumor-derived TGF␤ and PGE 2 stimulated macrophages to produce IL-10, which suppresses TNF and IL-12 production. However, the level of IL-10 in the macrophages cultured with the conditioned glioma medium was below the detectable limit in our experiments. Inaba, et al., 11 reported that PGE 2 production and the expression of COX-2 in monocytes or macrophages were induced by mucins secreted from human colon cancer cells. In our study, however, PGE 2 production by macrophages was not enhanced by bovine submaxillary mucins (data not shown). Accordingly, the glioma-derived soluble factors inducing PGE 2 production in macrophages seemed to be new molecules. We are now performing more precise analyses of the chemical nature of glioma-derived soluble factors.
It has been reported that macrophages infiltrate various tumor tissues and that tumor-associated macrophages have dual functions against tumor cells: one is to kill tumor cells, and the other is to promote tumor cell growth. The latter type of macrophages are so-called suppressor macrophages that can suppress T cell activation by releasing PGE 2 , IL-10, and TGF␤. 2, 14, 16, 21, 22, 24, 33 The mechanisms by which the suppressor macrophages are induced are still not clear, however. In the present report, we analyzed the interaction between macrophages and glioma in vitro as a model system for the glioma microenvironment. Our results suggested that the coculture of macrophages with glioma cells induces the production of a large amount of PGE 2 . Therefore, we determined that the interaction of macrophages and glioma cells induces suppressor macrophages, which exert suppressive activity on the immune system by producing elevated levels of PGE 2 in glioma-bearing hosts.
Concerning the mechanism by which glioma-derived soluble factors induce enhanced PGE 2 production by macrophages, we found that the expression of COX-2, and especially the expression of mPGES-1, was enhanced by glioma-derived soluble factors. There was no significant difference in the expression of cPLA 2 , sPLA 2 Type V, COX-1, or cPGES/p23 after treatment with the glioma-derived soluble factors (Fig. 6 ). It is known that COX-2 and mPGES-1 are inducible enzymes, 23 and mPGES-1 is proposed to be preferentially coupled with the inducible COX-2 to promote the final step of PGE 2 biosynthesis. 31 Reportedly, the induced expression of mPGES-1 is associated with various pathophysiological reactions, such as rheumatoid arthritis, 34 febrile response, 43 reproduction 6 and bone metabolism disorders, 27 and Alzheimer disease. 26 Recently, it was suggested that the expression of mPGES-1 in combination with COX-2 contributes to tumorigenesis. 15 Authors of these reports have indicated that PGE 2 production by tumor cells is related to tumor cell growth by inhibiting apoptosis and by inducing angiogenesis. 8, 35 Therefore, much attention has thus far been focused on the expression of mPGES-1 and the production of PGE 2 by tumor cells; conversely, there is little information about the expression of mPGES-1 and the production of PGE 2 by macrophages. Based on our findings, we posited that glioma induces COX-2 and mPGES-1 in macrophages, which consequently produce an enhanced amount of PGE 2 , and that this induction is one of the mechanisms of immunosuppression in glioma-bearing hosts. Moreover, it has been reported that COX inhibitors have an antitumor effect against various tumor cells, including glioma, 9, 13, 19, 32, 40, 45 and that the mechanism of this effect is mainly considered to be an inhibition of COX-2 in tumor cells. However, our results indicated that the target of COX inhibitors may be tumor-infiltrating macrophages, or both macrophages and tumor cells. Furthermore, as shown in Fig. 7 , mPGES-1 can be considered an important target for inducing an antiglioma effect given that IL-12 production was not clearly suppressed in mPGES-1-deficient mice. Thus, selective mPGES-1 inhibitors will be a possible candidate for the induction of antiglioma effects in the future.
Conclusions
We found that glioma produced soluble factors that stimulated macrophages to produce PGE 2 and impaired host immune responses. These soluble factors induced COX-2 and mPGES-1, especially the latter, in macrophages. This * The VM or RSV-M glioma (2 ϫ 10 5 /ml) was cultured for 48 hours, and cytokine production was detected using ELISA. Abbreviation: ND = under the detection limit. , B), or conditioned glioma medium (10%, C) for 6 hours and then treated with (black bars) or without (white bars) LPS (0.1 g/ml) for 18 hours. Production of PGE 2 was detected using EIA. Production was significantly enhanced compared with that in the control group (*p Ͻ 0.01).
mechanism is a new means of inducing an immunosuppressive state in glioma-bearing hosts. We consider the improvement of an immunosuppressive state to be required for the effective induction of antiglioma immune responses; therefore, the inhibition of PGE 2 synthesis is one of the treatments for improving an immunosuppressive state. Although further characterization of the glioma-derived soluble factors and clarification of the precise mechanism of enhanced PGE 2 production are required, we consider not only COX-2 but also mPGES-1 to be therapeutic targets for the antiglioma effect in the future.
